ORGANIZATION AND PLAN OF BUSINESS OPERATIONS (Details) $ in Millions |
9 Months Ended | ||
|---|---|---|---|
|
Nov. 16, 2021
USD ($)
|
Sep. 30, 2021
USD ($)
item
|
Mar. 31, 2021
USD ($)
|
|
| ORGANIZATION AND PLAN OF BUSINESS OPERATIONS | |||
| Number of branded drugs in product portfolio | item | 5 | ||
| Number of authorized generic prescription drugs | item | 3 | ||
| IPO | |||
| ORGANIZATION AND PLAN OF BUSINESS OPERATIONS | |||
| Proceeds of initial public offering | $ 31.2 | ||
| Subsequent Event | IPO | |||
| ORGANIZATION AND PLAN OF BUSINESS OPERATIONS | |||
| Proceeds of initial public offering | $ 31.2 | ||
| Convertible Class A Preferred | |||
| ORGANIZATION AND PLAN OF BUSINESS OPERATIONS | |||
| Preferred stock dividend rate | 8.00% | ||
| Working Line of Credit | East West Bank | |||
| ORGANIZATION AND PLAN OF BUSINESS OPERATIONS | |||
| Line of credit | $ 7.5 | $ 7.5 |
| X | ||||||||||
- Definition Number of authorized generic prescription drugs in current product portfolio. No definition available.
|
| X | ||||||||||
- Definition Number of branded drugs in current product portfolio. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The percentage rate used to calculate dividend payments on preferred stock. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's first offering of stock to the public. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|